AI illustration · not actual product photoDetails from the source.
Source-listed GHRP-2 Acetate (SKU G215): 15mg*10vials. PriceList(1).pdf lists 66 per 10 vials but does not specify currency; the website displays $66 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- G215
- Source specification
- 15mg*10vials
- Source document
- PriceList(1).pdf, page 2
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
GHRP-2 is a synthetic peptide described in human research as a growth-hormone secretagogue and ghrelin-receptor agonist. “Acetate” is the exact catalogue label; the exact salt, identity, purity, and contents of these supplier-specific vials have not been verified.
Biological mechanism
GHRP-2 stimulates endogenous growth-hormone release through the growth-hormone secretagogue/ghrelin-receptor pathway, involving pituitary and hypothalamic signaling. This pathway differs from the growth-hormone-releasing hormone receptor pathway. Findings about the molecule do not establish the contents or activity of the listed vials.
Research focus
Research has investigated GHRP-2 as a stimulus or probe for growth-hormone secretion and as a tool for studying ghrelin-related appetite and eating behavior. Human work has also examined endocrine responses in growth-related contexts. These are areas of investigation, not established uses for the catalogue item.
Potential applications in the evidence
Only potential applications investigated in research can be described: stimulation or assessment of growth-hormone responses and study of appetite regulation. Small, acute human experiments do not establish a treatment use, durable benefit, or efficacy of the listed products.
Human evidence
Small, short-term human studies report acute growth-hormone responses. One controlled study in seven healthy men found increased intake at a test meal after acute GHRP-2 exposure. Another study in six young adults found growth-hormone stimulation and changes in prolactin, ACTH, and cortisol. These studies do not establish clinical benefit, long-term outcomes, or safety of these SKUs.
Known and potential effects
Reported short-term human effects include stimulated growth-hormone release and, in small acute studies, increased appetite and changes in prolactin, ACTH, and cortisol. FDA describes serious-event reports among patients receiving GHRP-2, including increased insulin requirement to maintain blood glucose, deaths in critically ill study subjects, infection, and pancreatitis; FDA states causality has not been established. These are safety signals, not proof of causation or of effects from this product.
Safety and contraindications
FDA identifies potential immunogenicity risks for compounded GHRP-2 nominated for injectable and nasal use, including aggregation and peptide-related impurities, and notes that an unnatural amino acid complicates characterization. Endocrine and glucose-related effects and uncertain long-term safety are concerns. No product-specific FDA label or validated contraindication list for these catalogue SKUs was identified; the supplier has not documented vial contents, manufacturing, or quality.
U.S. FDA / regulatory status
No U.S. FDA approval for a GHRP-2 formulation was verified in the sources reviewed. FDA places bulk GHRP-2 nominated for injectable and nasal use in category 2 under the 503B interim policy and describes potential safety risks. That is not evidence that these catalogue vials are compounded and does not establish their approval or legal status. The catalogue does not identify manufacturer, lot, formulation source, jurisdiction, or approval documentation. Therefore, the exact vial cannot be verified as FDA-approved, compounded, or research-only; approval of an active ingredient or a different branded formulation would not transfer to this item.
Evidence limitations
Evidence is limited, including small acute human studies; long-term effects, uncommon harms, and efficacy for medical conditions remain unresolved. Animal and in-vitro findings are not human evidence. FDA notes that causality for the serious adverse-event reports has not been established. No study reviewed tests G25, G210, or G215, their contents, or their quality. The source list gives no currency for the listed prices. Do not infer exact vial identity from the compound name.
Supporting sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration · Regulatory safety page. Supports: FDA's category 2 listing for bulk GHRP-2 nominated for injectable and nasal use; immunogenicity and characterization concerns; serious-event reports and explicit causality caveat.
- Growth hormone releasing peptide-2 GHRP-2 like ghrelin increases food intake in healthy men Journal of Clinical Endocrinology & Metabolism; PubMed/NLM · Peer-reviewed human study record. Supports: Synthetic ghrelin agonist description and controlled acute study in seven healthy men reporting a growth-hormone response and increased test-meal intake.
- The Safety and Efficacy of Growth Hormone Secretagogues Sexual Medicine Reviews; PubMed Central/NLM · Peer-reviewed review. Supports: Secretagogue mechanism and context for growth-hormone and appetite research; review distinguishes evidence across secretagogues and describes the research landscape.
- Effects of GHRP-2 and hexarelin on GH prolactin ACTH and cortisol levels in man Peptides; PubMed/NLM · Peer-reviewed human study record. Supports: Small human comparison study reporting acute GH, prolactin, ACTH, and cortisol responses in young adults.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration · Regulatory compounding information. Supports: FDA's general 503A framework and distinction among compounding bulk-substance categories; does not assign this supplier-specific vial a status.
- Drug Approvals and Databases U.S. Food and Drug Administration · Official approval-database directory. Supports: Official FDA directory linking to Drugs@FDA approved-drug records; the exact vial's application and label remain unverified.